#5: TheMachine: ANDS Stock News : Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
ANA598 To Be Dosed for 12 Weeks in Triple Combination
SAN DIEGO, July 30... |
August 1, 2009
08:38:43 AM |
#4: TheMachine: ANDS Stock News : ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Data Being Presented Today at 44th Annual Meeting of EASL
Management to... |
May 25, 2009
11:59:08 PM |
#3: FastFun: Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.... |
October 15, 2007
11:52:51 PM |
#2: FastFun: Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
ANA598 demonstrates favorable preclinical antiviral, metabolic,... |
October 15, 2007
11:52:04 PM |
#1: Jason: ANDS, Anadys Pharmaceuticals Reports First Quarter 2007 Financial Results
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS Stock Forums), a biopharmaceutical... |
June 3, 2007
09:12:37 PM |
|
Tips for using stock message boards discussion forums
|
